Nirmatrelvir-Ritonavir Effective Against Omicron BA.4, BA.5 SARS-CoV-2 Variant
What was the real-world effect of nirmatrelvir-ritonavir treatment in outpatients with early COVID-19 infection during the Omicron-predominant period of the pandemic?
What was the real-world effect of nirmatrelvir-ritonavir treatment in outpatients with early COVID-19 infection during the Omicron-predominant period of the pandemic?
A study was conducted to compare the safety and efficacy of prophylactic and therapeutic anticoagulation in patients hospitalized with COVID-19.
Investigators assessed the change over time in COVID-19 vaccine effectiveness against infections, hospitalizations, and mortality for all virus variants and Omicron specifically.
Researchers assessed the prevalence of burnout and satisfaction with work-life integration among US physicians at the end of 2021 compared with previous years.
Researchers explored the use of D-dimer levels to rule out PTE in patients with COVID-19, as well as clinical associations between D-dimer levels and PTE.
Investigators sought to assess the effectiveness of heparin in patients hospitalized with COVID-19 and hypercoagulation.
Researchers sought to determine the outcomes for patients with multiple myeloma who develop bacterial meningitis.
In a randomized clinical trial, researchers evaluated clinical outcomes following fibrinogen administration in patients with severe TBI and concurrent hypofibrinogenemia.
Researchers sought to determine the risk for pulmonary embolism, deep vein thrombosis, and bleeding in patients recovering from COVID-19 infection.
Researchers sought to assess whether patients with migraine had a greater risk for PCiS than ACiS and if patients genetically predisposed to migraine showed an increased risk for PCiS or ACiS.